Documents
Application Sponsors
NDA 211710 | BAYER HEALTHCARE | |
Marketing Status
Application Products
001 | SOLUTION;ORAL | EQ 20MG BASE/ML | 1 | VITRAKVI | LAROTRECTINIB SULFATE |
FDA Submissions
TYPE 1; Type 1 - New Molecular Entity | ORIG | 1 | AP | 2018-11-26 | PRIORITY |
EFFICACY; Efficacy | SUPPL | 4 | AP | 2021-03-25 | STANDARD |
LABELING; Labeling | SUPPL | 5 | AP | 2021-03-25 | STANDARD |
LABELING; Labeling | SUPPL | 8 | AP | 2022-11-23 | STANDARD |
Submissions Property Types
ORIG | 1 | Null | 15 |
SUPPL | 4 | Null | 15 |
SUPPL | 5 | Null | 6 |
SUPPL | 8 | Null | 6 |
CDER Filings
BAYER HEALTHCARE
cder:Array
(
[0] => Array
(
[ApplNo] => 211710
[companyName] => BAYER HEALTHCARE
[docInserts] => ["",""]
[products] => [{"drugName":"VITRAKVI","activeIngredients":"LAROTRECTINIB SULFATE","strength":"EQ 20MG BASE\/ML","dosageForm":"SOLUTION;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
[labels] => [{"actionDate":"11\/26\/2018","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/211710s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"11\/26\/2018","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/211710s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2018\\\/211710Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2018\\\/210861Orig1s000_21171Orig1s000TOC.cfm\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2018-11-26
)
)